Immunologic and Prognostic Factors Associated with Overall Survival Employing a Poxviral-based PSA Vaccine in Metastatic Castrate-resistant Prostate Cancer

A concurrent multicenter, randomized Phase II trial employing a recombinant poxviral vaccine provided evidence of enhanced median overall survival (OS) (p=0.0061) in patients with metastatic castrate-resistant prostate cancer (mCRPC). The study reported here employed the identical vaccine in mCRPC t...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Gulley, James L., Arlen, Philip M., Madan, Ravi A., Tsang, Kwong-Yok, Pazdur, Mary P., Skarupa, Lisa, Jones, Jacquin L., Poole, Diane J., Higgins, Jack P., Hodge, James W., Cereda, Vittore, Vergati, Matteo, Steinberg, Seth M., Halabi, Susan, Jones, Elizabeth, Chen, Clara, Parnes, Howard, Wright, John J., Dahut, William L., Schlom, Jeffrey
Format: Artigo
Idioma:Inglês
Publicat: 2009
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2832083/
https://ncbi.nlm.nih.gov/pubmed/19890632
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-009-0782-8
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars